BPC-157 Under Review: What the FDA's 2026 Evaluation and the Published Studies Show

BPC-157 has an enormous online reputation and a small evidence base. In 2026 that gap became an official matter: the FDA wrote a detailed briefing document on the compound for its Pharmacy Compounding Advisory Committee, and the committee then voted against the agency staff's recommendation. This Vial Post explainer uses the FDA review, two 2025 literature reviews and the primary laboratory papers to lay out what is actually known, what is not, and where the regulatory picture stands in October 2026.

Nothing here is guidance on use in people or animals. The Vial Post covers BPC-157 strictly as a subject of laboratory and literature research.

Identity Card

• Sequence: H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH, a 15-residue chain (FDA PCAC briefing 2026).
• Formula and mass (free base): C62H98N16O22, 1419.5 g/mol (FDA PCAC briefing 2026).
• Other names: Bepecin and PL-14736 (FDA PCAC briefing 2026).
• Origin: described as a partial sequence of a larger "body protection compound" found in human gastric juice (Chang 2011). The FDA notes that it first appeared in the scientific literature in 1993 (FDA PCAC briefing 2026).
• Approval status: the FDA found no approved product containing BPC-157 in any country and no monograph in the European, Japanese or International pharmacopoeias (FDA PCAC briefing 2026).

Free Base or Acetate? Why the Label Matters

One detail that rarely appears in online discussion is that "BPC-157" can refer to two different active ingredients. The FDA treats BPC-157 free base and BPC-157 acetate as distinct bulk drug substances, each with its own UNII code and CAS number (137525-51-0 for the free base, 216441-37-1 for the acetate). Because the original nominations did not make clear which form was meant, the agency evaluated both on its own initiative (FDA PCAC briefing 2026).

The FDA's table writes the acetate as C62H98N16O22 with a variable number of acetic acid units and lists no single molecular weight for it (FDA PCAC briefing 2026). For laboratory work, that is a reason to check which form a Certificate of Analysis describes before calculating concentrations.

Stability Data the FDA Compiled

The briefing document gathers the published stability information in one place. Lyophilized free base is reported to be stable at room temperature for 3 weeks, but desiccated storage below -18 degrees C is recommended because moisture sharply reduces the long-term stability of freeze-dried peptides. Once in solution, it is reported to remain stable for 2 to 3 weeks at 4 degrees C and 3 to 4 months at -20 degrees C (FDA PCAC briefing 2026).

The same review cites an in-vitro report that BPC-157 resists hydrolysis in gastric juice, and attributes its very short half-life after intravenous administration in animals (5.3 minutes in dogs, 15.2 minutes in rats) to breakdown by blood or tissue peptidases (FDA PCAC briefing 2026). The FDA also cautions that peptides like this one can be extremely sensitive to formulation, process and conditions such as pH and temperature.

The Laboratory Evidence, Study by Study

Much of BPC-157's mechanistic literature comes from cell culture and rodent work. Four frequently cited papers show both what has been measured and how inconsistent the picture is.

Tendon explants and fibroblasts (Chang 2011). In rat Achilles tendon explants, BPC-157 accelerated fibroblast outgrowth. It did not directly change fibroblast proliferation in an MTT assay, but it increased cell survival under hydrogen peroxide stress, increased migration in a transwell assay in a dose-dependent way, and raised phosphorylation of FAK and paxillin without changing total protein levels (Chang 2011).

Growth hormone receptor expression (Chang 2014). A cDNA microarray in the same cell type flagged the growth hormone receptor as one of the most strongly up-regulated genes. BPC-157 increased receptor mRNA and protein in a dose- and time-dependent manner, and adding growth hormone to treated cells increased proliferation and activated JAK2 (Chang 2014).

VEGFR2 signaling (Hsieh 2017). In chick chorioallantoic membrane and endothelial tube-formation assays, BPC-157 increased vessel density. In human vascular endothelial cells it raised VEGFR2 mRNA and protein but not VEGF-A, promoted VEGFR2 internalization, and time-dependently activated VEGFR2-Akt-eNOS signaling; the endocytosis inhibitor dynasore blocked those effects (Hsieh 2017).

Alkali-burn model (Huang 2015). Topical BPC-157 was associated with faster wound closure in a rat alkali-burn model. In human umbilical vein endothelial cells it enhanced proliferation and migration, up-regulated VEGF-a, and changed ERK1/2 phosphorylation (Huang 2015).

Put side by side, these papers do not agree on a single pathway. One reports VEGFR2 up-regulation with no change in VEGF-A, while another reports VEGF-a up-regulation, and the tendon studies point to FAK-paxillin and growth hormone receptor signaling. The FDA's own conclusion is blunt: dose-response relationships have not been established, the molecular targets of BPC-157 have not been identified, and its mechanisms of action remain poorly understood (FDA PCAC briefing 2026).

How Thin the Human Record Is

• A 2025 systematic review in HSS Journal screened 544 articles published from 1993 to 2024 and kept 36: 35 preclinical studies and a single clinical study. It found no clinical safety data and noted that adverse effects are possible from unregulated manufacturing or contamination (Vasireddi 2025).
• A 2025 narrative review counted only three pilot studies in humans and concluded that rigorous, large-scale trials are lacking (McGuire 2025).
• One of those pilots, an intravenous safety study, enrolled two participants, both of whom had received the peptide before the study began (Lee & Burgess 2025).
• The FDA found no human pharmacokinetic data for oral, subcutaneous, nasal or transdermal administration. A ClinicalTrials.gov search turned up a single registered phase 1 study (NCT02637284) with no posted results and no associated publication (FDA PCAC briefing 2026).

The FDA summarized the situation by stating that there is insufficient clinical safety information to characterize the safety profile of either form (FDA PCAC briefing 2026).

Regulatory Timeline

Earlier listing: BPC-157 was placed in category 2 of the FDA's interim compounding policies, the group of bulk substances flagged as possibly presenting significant safety risks. The nominations were later withdrawn, and the FDA's page now lists it among substances "nominated but withdrawn," with a note on possible immunogenicity, peptide-related impurities and limited safety information (FDA bulk substances page, accessed October 2026).

Sport: BPC-157 appears on the World Anti-Doping Agency prohibited list under non-approved substances, section S0 (FDA PCAC briefing 2026).

May 2023: New Zealand's Medicines Classification Committee proposed classifying BPC-157 as a prescription medicine (FDA PCAC briefing 2026).

July 23, 2026: At the advisory committee meeting, FDA reviewers recommended against adding BPC-157 to the 503A bulks list. The committee voted 8 to 6, with 1 abstention, to recommend it anyway. The vote is nonbinding: the FDA would still need to accept it and complete notice-and-comment rulemaking before pharmacies could legally compound the substance (AJMC 2026).

October 2026: The FDA sent an interim peptide compounding policy to the White House for review, and BPC-157 has been reported, citing unnamed sources, as one of the peptides covered. Our news report on the interim compounding policy follows that story.

Questions Readers Ask

Is BPC-157 an approved drug anywhere? The FDA found no approved product containing it in any country (FDA PCAC briefing 2026).

Did the July 2026 vote make BPC-157 legal to compound? No. Committee recommendations are advisory, and adding a substance to the 503A list requires a proposed rule, public comment and a final rule (AJMC 2026).

Is every product labeled "BPC-157" the same substance? Not necessarily. The free base and the acetate are separate active ingredients with different identifiers (FDA PCAC briefing 2026).

Where should a lab start when sourcing it? With documentation. For laboratory work, BPC-157 research material from Dynamite Research Peptides is supplied with a batch Certificate of Analysis, and any supplier's COA should state the salt form, purity method and lot number.

For research and educational use only. This article is not medical advice and does not describe dosing or human use.